Full text is available at the source.
Abstract
Patients with type 2 diabetes (T2D) present an increased risk of developing Alzheimer's disease (AD).
- There is a suggested relationship between diabetes and cognitive decline.
- Brain insulin resistance is a key factor in the transition from mild cognitive impairment to Alzheimer's disease.
- Glucose-lowering drug classes, such as glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter inhibitors, may have neuroprotective effects.
- These medications could positively influence cognitive function through various mechanisms, including reducing inflammation and enhancing insulin signaling.
- Current clinical trials are investigating the effectiveness of these drugs in preventing neurodegenerative decline.
- Larger, randomized, and controlled trials with longer follow-up are needed to confirm the potential of these therapies in clinical practice.
Simplified